Grace Therapeutics, Inc.
GRCE
$2.27
-$0.03-1.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 67.20% | 31.59% | 5.71% | -5.32% | -1.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.38% | -33.88% | -47.65% | -37.74% | 0.25% |
| Operating Income | 5.38% | 33.88% | 47.65% | 37.74% | -0.25% |
| Income Before Tax | -653.40% | 51.37% | 78.10% | -0.63% | 90.58% |
| Income Tax Expenses | -66.99% | -- | -- | -- | -14.51% |
| Earnings from Continuing Operations | -285.22% | 44.28% | 72.67% | -28.47% | 120.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -285.22% | 44.28% | 72.67% | -28.47% | 120.09% |
| EBIT | 5.38% | 33.88% | 47.65% | 37.74% | -0.25% |
| EBITDA | 5.38% | 33.93% | 47.63% | 37.77% | -0.22% |
| EPS Basic | -248.48% | 62.14% | 80.25% | 11.86% | 116.70% |
| Normalized Basic EPS | -505.81% | 66.98% | 84.19% | 30.93% | 92.02% |
| EPS Diluted | -248.48% | 62.14% | 80.25% | 11.86% | 116.70% |
| Normalized Diluted EPS | -505.81% | 66.98% | 84.19% | 30.93% | 92.02% |
| Average Basic Shares Outstanding | 24.77% | 47.17% | 38.40% | 45.72% | 20.35% |
| Average Diluted Shares Outstanding | 24.77% | 47.17% | 38.40% | 45.72% | 20.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |